RxDoctor Payments Data

Robert Vonderheide

Medical Oncology · Philadelphia, PANPI 1902849219

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $10,065 of the $10,131 with a category attached, or 99.4%. 4 manufacturers reported payments, led by E.r. Squibb & Sons, L.L.C. at 58.2% of the total. Reporting peaked in 2023 at $5,850 and has fallen 99.6% since, to $21 in 2025.

$10,131in general payments, 2019–2025

Across 6 payments — averaging $1688.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$6K
  • Bristol Myers Squibb$3K
  • EMD Serono Research & Development Institute, Inc.$1K
  • Lilly USA, LLC$21
$1,893,225in research payments, 2019–2025

Across 3 payments — averaging $631,075 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • E.r. Squibb & Sons, L.L.C.$1.9M

What the payments were for

  • Consulting fees$10,06599%
  • Food & beverage$661%

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$10,131 in reported general payments places this provider in the 65th percentile of 238 medical oncology providers in Pennsylvania.

See all medical oncology providers in Pennsylvania →

Other medical oncology in Philadelphia

See the full list for Pennsylvania →

Where these figures come from

Is this you, or does something look wrong? →